Real-world implementation of large-panel ctDNA NGS testing in metastatic NSCLC and colorectal cancer across a public healthcare system: interim results of the multicenter LOLA Project

ESMO 2026

Oct 23, 2026
Oncology
Presentation

Valeria C. Denninghoff, Encarnación Gonzalez, Manuel J. Valladares Ayerbes, Victoria Eugenia C. Castellon Rubio, Javier Valdivia-Bautista, Esperanza Arriola Arellano, Ana Laura Ortega Granados, Begona Medina Magan, Isidoro C. Barneto Aranda, Julia Alcaide-Garcia, Manuel A. Cobo Dols, Silvia Sequero Lopez, Angel Inoriza, Amparo Sanchez Gastaldo, Amelia Muñoz-Lerma, Maria Auxiliadora Gómez España, Abel Garcia, Cristobal Fresno, María José Serrano

Background
Comprehensive molecular profiling is essential for precision oncology in metastatic non-small cell lung cancer (mNSCLC) and metastatic colorectal cancer (mCRC). However, tissue limitations and prolonged turnaround times (TAT) frequently compromise biomarker-guided treatment decisions. We evaluated the implementation of plasma ctDNA next-generation sequencing (NGS) across a regional public healthcare network.

 

Methods
LOLA (Liquid Biopsy, Lung and Colon Cancer in Andalusia; NCT06997458) is an ongoing prospective multicenter implementation study across 11 hospitals of the Andalusian Public Health System. Treatment-naïve patients with mNSCLC and mCRC were prospectively enrolled using harmonized regional workflows for blood collection, centralized molecular analysis and clinical reporting. Plasma samples were analysed using a 105-gene ctDNA sequencing assay (Tempus xF®). Reportability, actionable alterations, TAT and clinical impact were evaluated.

 

Results
Between July 2024 and mid-2025, 250 patients were enrolled. Among 244 collected plasma samples, 235 generated evaluable NGS reports, corresponding to a 94% effective reportability rate after repeat sampling. Median TAT for successfully processed first-attempt samples was 10 days. Clinically actionable alterations were identified in 109/235 patients (46%). ctDNA results modified therapeutic decision-making in 21 patients, including treatment selection and clinical trial enrolment. Resistance-associated alterations were identified before tissue-based testing in selected cases.

 

Conclusions
The LOLA Project demonstrates the feasibility and clinical utility of centralized large-panel ctDNA testing across a regional public healthcare network. This real-world strategy achieved high reportability rates, rapid TAT and clinically actionable molecular profiling with measurable impact on therapeutic decision-making in mNSCLC and mCRC.